About Us

The Company’s Strategies

Celgenics is begining research into the detection and isolation of actinomycetes, for the tests of activity against Cancer Stem Cells and other substrates.
Celgenics also intends to begin research into the use of Adult Stem cells in various other areas. These may include: Alzheimers, Diabetes, Multiple Slerosis and regeneration of damaged tissue such as spinal cord or heart. Rejuvenation and anti-aging treatment strategies will also be considered.

Actinomycetes

Actinomycetes are a group of micro-organisms some of which can produce unique bioactive compounds including antibiotics and anticancer compounds.
Actinomycetes, have been the greatest source of antibiotics since the discovery of Streptomycin in 1944. Since then, actinomycetes have provided approximately two thirds of the naturally occurring antibiotics.

Recently reported, (from New Scientist, 22 August 2009) MIT Biologistics found an actinomycetes derivative, Salinomycin which killed reprogrammed cancer ‘stem cells’. Earlier studies undertaken by one of the Celgenics proposed directors, Dr Keast, showed that the Western Australian soils contain many new species of actinomycetes.

Celgenics has a Joint Venture (subject to shareholder approval) with ASX listed Actinogen Limited for access to its unique Actinomycetes library. Some Australian Actinomycetes have not been found elsewhere in the world.